Admin Login      My Saved Results      Contact Us      News & Events FaceBook Twitter YouTube LinkedIn

Atlanta Cancer Care - Decatur

printPrint Results Email Results Save Results
Atlanta Cancer Care is a medical oncology practice with ten physicians practicing at six offices located around the metropolitan Atlanta area. Atlanta Cancer Care is accredited by the American College of Radiology (ACR). The Atlanta Cancer Care practice is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers. Atlanta Cancer Care provides laboratory, infusion, supportive care, and diagnostic services in all of its offices. The majority of chemotherapy treatment is provided in the Atlanta Cancer Care office, rather than the hospital. Atlanta Cancer Care participates in clinical trials which use chemotherapy drugs, and/or other drugs which affect cancer cells. Pain management, evaluation for clinical trials, behavioral health, nutrition, home health and hospice, and financial counseling services are all provided and/or coordinated by the Atlanta Cancer Care staff. Atlanta Cancer Care strives to treat the whole person and family including emotional, spiritual, nutritional, and pain management needs.

Treatment Sites in Georgia

Primary Location

2665 North Decatur Road
Suite 740
Decatur, GA 30033
404-321-1950 (p)
404-633-9838 (f)
www.atlantacancercare.com

driving directions

Clinical Trials in Georgia

A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Cancer Type: Brain Cancer
Study Coordinator: Julie Carney - (404) 290-3941


A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship Between Patient Outcomes, Treatment Regimens and Molecular Profiles
Cancer Type: Multiple Myeloma
Study Coordinator: Julie Carney - (404) 290-3941


Phase III Randomized Study of Stereotactic Radiosurgery With Versus Without Whole-Brain Radiotherapy in Patients With Cerebral Metastases
Cancer Type: Metastases
Study Coordinator: Julie Carney - (404) 290-3941


Phase III Randomized Study of Adjuvant Rosuvastatin in Patients With Resected Stage I or II Colon Cancer
Cancer Type: Colon/Rectal Cancer
Study Coordinator: Julie Carney - (404) 290-3941


Phase III Randomized Study of Prostate Bed Radiotherapy (PBRT) Alone Versus Short Term Androgen Deprivation Comprising Antiandrogen and Luteinizing Hormone-Releasing Hormone Agonist Therapy and Pelvic Lymph Node Radiotherapy With Versus Without PBRT i
Cancer Type: Prostate Cancer
Study Coordinator: Julie Carney - (404) 290-3941


Phase III Randomized Study of Adjuvant Chemotherapy With Versus Without Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Julie Carney - (404) 290-3941


Phase III Randomized Study of Adjuvant FOLFOX Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Celecoxib in Patients With Resected Stage III Colon Cancer
Cancer Type: Colon/Rectal Cancer
Study Coordinator: Julie Carney - (404) 290-3941


Phase III Randomized Study of Carboplatin and Paclitaxel or Carboplatin, Paclitaxel, and Bevacizumab With Versus Without Concurrent Cetuximab in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer
Study Coordinator: Julie Carney - (404) 290-3941


Phase III Randomized Study of Early Local Therapy Comprising Surgery Versus Standard Palliative Therapy for the Intact Primary Tumor in Patients With Stage IV Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Julie Carney - (404) 290-3941


Phase III Randomized Study of Radiotherapy With Versus Without Trastuzumab (Herceptin®) in Women With HER2-Positive Ductal Carcinoma In Situ Who Underwent Lumpectomy
Cancer Type: Breast Cancer
Study Coordinator: Julie Carney - (404) 290-3941


Phase III Randomized Study of Standard Adjuvant Endocrine Therapy With Versus Without Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive, and HER2-Negative Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Julie Carney - (404) 290-3941